Boehringer Ingelheim’s HIV Therapy Aptivus Gets Full FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Protease inhibitor received accelerated approval in June 2005, but FDA requested additional post-marketing trials.
You may also be interested in...
Boehringer’s Aptivus Approved For HIV In Kids
New oral solution gets approval for adults, too.
Boehringer’s Aptivus Approved For HIV In Kids
New oral solution gets approval for adults, too.
Aptivus Adds Warning On Intracranial Hemorrhaging To Black Box
Labeling for Boehringer Ingelheim’s HIV drug was updated based on Phase III data of tipranavir coadministered with ritonavir (Abbott’s Norvir).